Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
By
Yi-Heng Xu
Dan Liu
Meng-Rui Zhang
Yi-Jing Zhang
Ming Li
Qing-Rui Yang
May 20, 2026
Clinical Scorecard: Effectiveness and Safety of Upadacitinib for Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
At a Glance
Category Detail
Condition Rheumatoid Arthritis Key Mechanisms Selective Janus kinase 1 (JAK1) inhibitor blocking pro-inflammatory cytokine signaling pathways. Target Population Patients with rheumatoid arthritis exhibiting inadequate response to conventional synthetic DMARDs. Care Setting Outpatient and clinical trial settings.
Key Highlights
Upadacitinib significantly improved ACR20 response rates at 12 weeks compared to control. Both 15 mg and 30 mg doses showed comparable efficacy. Higher dose (30 mg) associated with increased risk of adverse events. Guideline-Based Recommendations
Diagnosis
Diagnosis of RA based on clinical criteria and imaging. Management
First-line therapy with csDMARDs, escalation to biologic or targeted therapies as needed. Monitoring & Follow-up
Regular monitoring for adverse events, particularly infections and liver function. Risks
Increased risk of serious infections, herpes zoster, and elevated liver enzymes. Patient & Prescribing Data
Adults with rheumatoid arthritis, particularly those with inadequate response to methotrexate.
15 mg dose may offer a more favorable benefit-risk balance compared to 30 mg.
Clinical Best Practices
Consider patient-specific factors when prescribing upadacitinib. Monitor for adverse events, especially in high-risk populations. Related Resources & Content
